Detalles de la búsqueda
1.
Letter to the editor concerning the article: 'Potential cerebrovascular accident signal for risankizumab: A disproportionality analysis of the FDA adverse event reporting system (FAERS)'.
Br J Clin Pharmacol;
89(8): 2639-2641, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37114281
2.
Baseline characteristics and treatment-emergent risk factors associated with cerebrovascular event and death with risperidone in dementia patients.
Br J Psychiatry;
209(5): 378-384, 2016 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-27388570
3.
An analysis of potentially prolactin-related adverse events and abnormal prolactin values in randomized clinical trials with paliperidone palmitate.
Ann Pharmacother;
46(10): 1322-30, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-22947594
4.
A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia.
BMC Psychiatry;
12: 26, 2012 Mar 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-22455454
5.
Exposure to Infliximab During Pregnancy: Post-Marketing Experience.
Drug Saf;
43(2): 147-161, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31677004
6.
Risperdal® CONSTA® Needle Detachment. Incidence Rates Before and After Kit Redesign: A Retrospective Study using Electronic Health Records and Natural Language Processing in the Department of Veterans Affairs.
Neurol Ther;
8(1): 95-108, 2019 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-30847767
7.
Evaluating the postmarketing experience of risperidone use during pregnancy: pregnancy and neonatal outcomes.
Drug Saf;
30(3): 247-64, 2007.
Artículo
en Inglés
| MEDLINE | ID: mdl-17343431
8.
Prolongation of cardiac ventricular repolarization under paliperidone: how and how much?
J Cardiovasc Pharmacol;
59(3): 298-9, 2012 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-22410947
9.
Drug-Drug Interaction Studies of Paliperidone and Divalproex Sodium Extended-Release Tablets in Healthy Participants and Patients with Psychiatric Disorders.
J Clin Pharmacol;
56(6): 683-92, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-26412032
10.
Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial.
JAMA Psychiatry;
72(8): 830-9, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-25820612
11.
A Post-hoc comparison of paliperidone palmitate to oral risperidone during initiation of long-acting risperidone injection in patients with acute schizophrenia.
Innov Clin Neurosci;
8(8): 26-33, 2011 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-21922067
12.
Efficacy and Safety of Paliperidone Extended Release 1.5 mg/day-A Double-blind, Placebo- and Active-Controlled, Study in the Treatment of Patients with Schizophrenia.
Psychopharmacol Bull;
44(2): 54-72, 2011 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-27738355
13.
Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia.
Neuropsychiatr Dis Treat;
7: 93-101, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-21552311
14.
Regarding "A Risperidone-induced Prolactinoma Resolved When A Woman with Schizoaffective Disorder Switched to Ziprasidone: A Case Report".
Innov Clin Neurosci;
10(2): 12-6, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-23556137
Resultados
1 -
14
de 14
1
Próxima >
>>